Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza

Journal of Clinical Virology

Volumn 50, Issue 2, 2011, Pages 114-118

  Alonso, María ^a,b   Rodríguez Sánchez, Belén ^a,b   Giannella, Maddalena ^a   Catalán, Pilar ^a,b   Gayoso, Jorge ^a   López Bernaldo de Quirós, Juan Carlos ^a   Bouza, Emilio ^a,b   De Viedma, Darío García ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

H1N1 2009; Influenza; Mutations; Persistent infection; Resistance; Virulence

Indexed keywords

OSELTAMIVIR; ZANAMIVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; D225G GENE; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; INFLUENZA A (H1N1); MALE; PANDEMIC; PERSISTENT INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS GENE; VIRUS RESISTANCE; VIRUS VIRULENCE;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NEURAMINIDASE; OSELTAMIVIR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRULENCE; ZANAMIVIR;

EID: 78951490504     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.10.007     Document Type: Article

References (20)

1. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008, 52(9 (September)):3284-3292.
2. Organization WH. Oseltamivir resistance in immunocompromised hospital patients, ; 2009 [accessed 12.02.09]. http://wwwwhoint/csr/disease/swineflu/notes/briefing_20091202/en/indexhtml.
3. Le Q.M., Wertheim H.F., Tran N.D., van Doorn H.R., Nguyen T.H., Horby P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2010, 362(1 (January 7)):86-87.
4. Abed Y., Baz M., Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 2006, 11(8):971-976.
5. Glaser L., Stevens J., Zamarin D., Wilson I.A., Garcia-Sastre A., Tumpey T.M., et al. A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol 2005, 79(17 (September)):11533-11536.
6. Kilander A., Rykkvin R., Dudman S.G., Hungnes O. Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009-2010. Euro Surveill 2010, 15(9).
7. Zheng B., Chan K.H., Zhang A.J., Zhou J., Chan C.C., Poon V.K., et al. D225G mutation in hemagglutinin of pandemic influenza H1N1 (2009) virus enhances virulence in mice. Exp Biol Med (Maywood) 2010, 235(8 (August)):981-988.
8. Liu Y., Childs R.A., Matrosovich T., Wharton S., Palma A.S., Chai W., et al. Altered receptor specificity and cell tropism of D222G haemagglutinin mutants from fatal cases of pandemic A(H1N1) 2009 influenza. J Virol 2010, September 8.
9. Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999, 41:95-98.
10. Memoli M.J., Hrabal R.J., Hassantoufighi A., Eichelberger M.C., Taubenberger J.K. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010, 50(9 (May 1)):1252-1255.
11. Birnkrant D., Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009, 361(23 (December 3)):2204-2207.
12. Wang B., Dwyer D.E., Blyth C.C., Soedjono M., Shi H., Kesson A., et al. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antiviral Res 2010, April 10.
13. Zonis Z., Engelhard D., Hindiyeh M., Ram D., Mandelboim M., Mendelson E., et al. Community-acquired oseltamivir-resistant pandemic (H1N1) 2009 in child, Israel. Emerg Infect Dis 2010, 16(6 (June)):1045-1046.
14. Hindiyeh M., Ram D., Mandelboim M., Meningher T., Hirsh S., Robinov J., et al. Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time reverse transcriptase PCR. J Clin Microbiol 2010, 48(5 (May)):1884-1887.
15. Deyde V.M., Sheu T.G., Trujillo A.A., Okomo-Adhiambo M., Garten R., Klimov A.I., et al. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 2010, 54(3 (May)):1102-1110.
16. Gooskens J., Jonges M., Claas E.C., Meijer A., Kroes A.C. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009, 199(10 (May 15)):1435-1441.
17. Miller R.R., MacLean A.R., Gunson R.N., Carman W.F. Occurrence of haemagglutinin mutation D222G in pandemic influenza A(H1N1) infected patients in the West of Scotland, United Kingdom, 2009-10. Euro Surveill 2010, 15(16).
18. Anton A., Marcos M.A., Martinez M.J., Ramon S., Martinez A., Cardenosa N., et al. D225G mutation in the hemagglutinin protein found in 3 severe cases of 2009 pandemic influenza A (H1N1) in Spain. Diagn Microbiol Infect Dis 2010, 67(2 (June)):207-208.
19. Potdar V.A., Chadha M.S., Jadhav S.M., Mullick J., Cherian S.S., Mishra A.C. Genetic characterization of the influenza A pandemic (H1N1) 2009 virus isolates from India. PLoS One 2010, 5(3):e9693.
20. Chen H., Wen X., To K.K., Wang P., Tse H., Chan J.F., et al. Quasispecies of the D225G substitution in the hemagglutinin of pandemic influenza A(H1N1) 2009 virus from patients with severe disease in Hong Kong, China. J Infect Dis 2010, 201(10 (May 15)):1517-1521.